BIOGEN INC.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- BIIB [1]
- Listing exchanges
- Nasdaq [1]
- SEC industry
- Biological Products, (No Diagnostic Substances) [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- BIOGEN INC. [1]
- Headquarters location
- Cambridge [2]
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142 [1]
- Founded
- 1978 [2]
- Legal form
- Delaware corporation [2]
- Incorporation jurisdiction
- Delaware, United States [1]
- Leadership in background record
- Michel Vounatsos [2]
- Founders
- Charles Weissmann; Walter Gilbert; Phillip Sharp; Kenneth Murray [2]
- Official website
- www.biogen.com ↗ [2]
- Annual revenue
- USD 10,173,400,000 · reported year 2022 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US09062X1037 [2]
- CIK
- 0000875045 [1]
- SIC code
- 2836 [1]
- Country in background record
- United States [2]
Company positioning and business
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues). [3]
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. [3]
Background text: Wikipedia contributors, Biogen. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Management and corporate governance
The Wikidata background record identifies Michel Vounatsos in the chief-executive role. This background entry is not an official confirmation of the current board or executive roster. [2]
Understanding company scale
Annual revenue: USD 10,173,400,000 · reported year 2022. [2]
Financial year, securities and disclosures
The SEC submissions record gives BIOGEN INC. a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: BIIB (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2836. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was BIOGEN INC. founded?
Founded: 1978. The linked source provides the background record. [2]
Where is the headquarters of BIOGEN INC.?
Headquarters location: Cambridge. The linked source provides the background record. [2]
Which business sectors are recorded for BIOGEN INC.?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
BIOGEN INC. relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — BIOGEN INC. filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Biogen (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.